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INTRODUCTION
Brain ischemia, also known as cerebral ischemia or ischemic
stroke, is the third most common cause of death worldwide, after
heart attack and cancer, resulting in major negative social and
economic consequences. Ischemic stroke, which results from
cardiac arrest, cerebral arterial occlusion or severe vasospasm after
subarachnoid ischemia, causes devastating damage to the brain and
represents a serious global health problem. Briefly, brain ischemia
is a condition in which there is insufficient blood flow to meet
metabolic demands. It is known that an interruption of blood flow
to the brain for more than 10 seconds results in a loss of
consciousness, leading to ischemia and irreversible brain damage.
The most common cause of stroke is the sudden occlusion of a
blood vessel by a thrombus or embolism, resulting in an almost
immediate loss of oxygen and glucose to the cerebral tissue.
Ischemia can be classified as either focal or global. Focal ischemia
is confined to a specific lesion, whereas global ischemia
encompasses a wide area of the brain (see Gusev and Skvortsova,
2003).
Given the clinical importance of ischemia, it is not surprising
that its causes, diagnosis and treatment are the focus of a major
international research effort (see Liebeskind, 2008; Slemmer et al.,
2008; Dogrukol-Ak et al., 2009; Indraswari et al., 2009; Kim et al.,
2009; Chauveau et al., 2010; Gupta et al., 2010; Henninger et al.,
2010; Rymner et al., 2010; Cucchiara and Kasner, 2011; Yenari and
Hemmen, 2010; Fisher, 2011; Kunst and Schaefer, 2011; Leiva-
Salinas et al., 2011; Molina, 2011; Ramos-Fernandez et al., 2011;
Turner and Adamson, 2011; Wechsler, 2011). To provide an idea
of the volume of research carried out in this area, a keyword search
on May 16th, 2011 using the PubMed National Center for
Biotechnology Information (NCBI) search engine revealed 78,103
articles containing the search term ‘brain ischemia’. More
specifically, there were 58,357 articles containing both ‘brain
ischemia’ and ‘human’, and 28,253 containing both ‘brain ischemia’
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SUMMARY
Brain ischemia, also termed cerebral ischemia, is a condition in which there is insufficient blood flow to the brain to meet metabolic demand, leading
to tissue death (cerebral infarction) due to poor oxygen supply (cerebral hypoxia). Our group is interested in the protective effects of neuropeptides
for alleviating brain ischemia, as well as the underlying mechanisms of their action. The present study was initiated to investigate molecular responses
at the level of gene expression in ischemic brain tissue. To achieve this, we used a mouse permanent middle cerebral artery occlusion (PMCAO)
model in combination with high-throughput DNA microarray analysis on an Agilent microarray platform. Briefly, the right (ipsilateral) and left
(contralateral) hemispheres of PMCAO model mice were dissected at two time points, 6 and 24 hours post-ischemia. Total RNA from the ischemic
(ipsilateral) hemisphere was subjected to DNA microarray analysis on a mouse whole genome 4x44K DNA chip using a dye-swap approach. Functional
categorization using the gene ontology (GO, MGD/AMIGO) of numerous changed genes revealed expression pattern changes in the major categories
of cellular process, biological regulation, regulation of biological process, metabolic process and response to stimulus. Reverse-transcriptase PCR
(RT-PCR) analysis on randomly selected highly up- or downregulated genes validated, in general, the microarray data. Using two time points for this
analysis, major and minor trends in gene expression and/or functions were observed in relation to early- and late-response genes and differentially
regulated genes that were further classified into specific pathways or disease states. We also examined the expression of these genes in the contralateral
hemisphere, which suggested the presence of bilateral effects and/or differential regulation. This study provides the first ischemia-related
transcriptome analysis of the mouse brain, laying a strong foundation for studies designed to elucidate the mechanisms regulating ischemia and
to explore the neuroprotective effects of agents such as target neuropeptides.
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and ‘animal’, whereas ‘brain ischemia’ and ‘rat’, and ‘brain ischemia’
and ‘mouse’ revealed 9109 and 3912 articles, respectively. The
subject has also been widely reviewed, with a PubMed search using
both the keywords ‘brain ischemia’ and ‘review’ resulting in a total
of 9478 articles. In order to understand the pathology of stroke,
targeted gene expression and proteomics studies have been carried
out to investigate the role of particular genes and proteins.
Decreased blood flow during ischemia activates the synthesis of
various genes and proteins that regulate the ischemic process
and/or are involved in the broader cellular response, depending on
the extent of the injury. Among these molecular factors, we are
also likely to find potentially protective genes and/or proteins.
Our group has been working on ischemic models since 1994
(Mizushima et al., 1994; Shimazu et al., 1994), with the goal of
understanding the mechanisms underlying ischemia and identifying
molecular targets for its prevention or amelioration, including the
use of neuropeptides such as pituitary-adenylate-cyclase-activating
polypeptide (PACAP). This has led to the successful
characterization of certain molecular components involved in
cerebral ischemia and the establishment of PACAP as a potential
therapeutic agent for its prevention (Shioda et al., 1998; Ohtaki et
al., 2003; Ohtaki et al., 2006; Ohtaki et al., 2007; Ohtaki et al., 2008a;
Ohtaki et al., 2008b; Nakamachi et al., 2005; Nakamachi et al., 2010).
The crucial issue now is to elucidate exactly how any identified
neuroprotective molecules exert their effects.
Over the last decade, and particularly within the last 3 years,
researchers have begun focusing their attention on genomic
approaches to investigate brain ischemia and physiological
responses to it (Jin et al., 2001; Büttner et al., 2008; Meschia, 2008;
Qin et al., 2008; Juul et al., 2009; Grond-Ginsbach et al., 2009;
Haramati, 2009; Nakajima, 2009; Popa-Wagner et al., 2009; Yao
et al., 2009; Di Pietro et al., 2010; Pruissen et al., 2009; Stamova
et al., 2010; Zhan et al., 2010). These studies have shown the
importance of high-throughput transcript profiling, such as the
DNA microarray technique (DeRisi et al., 1997), for gaining
insight into the ischemic brain. In the present study, we have taken
a different approach to the problem, and have adopted a whole
genome DNA microarray analysis approach (Masuo et al., 2011b)
as a means of providing an inventory of the time-dependent
changes in global gene expression that occur at the mRNA level
in mice in response to ischemia. To achieve this, we have utilized
a mouse model of permanent middle cerebral artery occlusion
(PMCAO) (Nakamachi et al., 2005; Nakamachi et al., 2010) (see
supplementary material Fig. S1). Briefly, total RNA was extracted
at 6 and 24 hours from very fine powders of post-ischemic brain
tissue, then subjected to DNA microarray analysis using a mouse
whole genome DNA chip (4x44K) with a dye-swap approach,
followed by identification of changes in gene expression. Our
results revealed a large number of highly up- and downregulated
genes, whose involvement in the progression of and response to
ischemia is discussed in this paper.
RESULTS AND DISCUSSION
PMCAO-generated ischemia model mice
PMCAO (supplementary material Fig. S1B,D) was performed on
13 male mice (C57/BL6J), and the results of the procedure were
monitored by dissecting whole brains and visualizing the extent of
ischemia. Eleven mice (84.6%) survived the PMCAO procedure
(data not shown). In addition, a total of ten sham (control) mice
were used. We also injected 0.9% saline intracerebroventrically in
both the sham control and PMCAO model mice, consistent with
our long-term goal of determining whether various neuropeptides
can reverse the effects of ischemia. Injection of saline was to the
left hemisphere (contralateral; supplementary material Fig. S1C).
The ischemic region was visualized by 2% 2,3,5-
triphenyltetrazolium chloride (TTC; Wako, Tokyo, Japan) in some
mice to confirm the ischemic brain damage (supplementary
material Fig. S1E). Moreover, we also checked for neurological
deficiency 24 hours after PMCAO, using a routinely used
methodology in our laboratory (Ohtaki et al., 2006; Dogrukol-Ak
et al., 2009). Results showed neurological deficiency in 85% of these
animals (PMCAO mice); these were used for dissection of the brain
tissues. After perfecting the technique, mice were divided into four
groups of three mice each for the control and PMCAO cohorts,
and whole brains were dissected following 6 or 24 hours of
ischemia. The ipsilateral (right hemisphere; non-injected) and
contralateral (left hemisphere; injected with saline) hemispheres
without olfactory bulb (OB) and cerebellum (supplementary
material Fig. S1F,G) were quickly separated, placed in 2.0 ml
Eppendorf tubes, and deep frozen in liquid nitrogen.
Overview of the brain genomic response to ischemia
Quality of total RNA and level of GAPDH and -actin genes in the
brain hemispheres
To investigate global changes in gene expression in ischemic
hemispheres, we first optimized a protocol for total RNA extraction
(Fig. 1; supplementary material Figs S2, S3). Here we would like to
clarify that we refer to the ischemic brain hemisphere (ipsilateral)
as consisting of the infarct core, penumbra and non-ischemic region
under the present experimental design and sampling of the brain
tissue thereof. This provides an overall picture of the ischemic brain
hemisphere rather than one specific ischemic region. Nevertheless,
in the future it would be interesting to examine specific ischemic
regions and compare them with non-ischemic regions in the same
hemisphere. The quantity and quality of the total RNA, a crucial
factor in further downstream analyses, was confirmed, and this
RNA was then used for synthesizing cDNA. Prior to DNA
microarray analysis, we examined the expression of two commonly
used house-keeping genes, namely glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) and -actin (supplementary material
Table S1), in both hemispheres at 6 and 24 hours. This allowed us
to subsequently use these two genes as positive controls rather than
simply loading or using internal controls (see Suzuki et al., 2000).
This simple test of gene expression showed that the mRNAs for
GAPDH and -actin were expressed almost uniformly across
conditions (supplementary material Fig. S4). Following this
preliminary analysis of sample quantity and quality, we proceeded
to conduct a DNA microarray analysis using the ischemic
(ipsilateral) brain hemisphere.
Changes in gene expressions in the ischemic brain and their
functional categorization
Using the total RNA in the ischemic hemisphere and the 4x44K
mouse whole genome DNA microarray chip in conjunction with a
dye-swap approach (as explained in the Methods), genome-wide
global gene expression profiles were obtained for ischemia-related
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genes. The results revealed 1237 and 2759 cases of gene induction
(>1.5-fold) as compared with 620 and 2102 cases of gene suppression
(<0.75-fold) at 6 and 24 hours after PMCAO, respectively (Fig. 2).
These genes are shown in supplementary material Tables S2-S5. For
detailed information on the changed gene expression profiles, readers
are referred to the total gene expression data files at the NCBI GEO
data (GSE 28201) repository, submitted as part of this publication.
Interestingly, the majority of these changes were unique to either the
6- or 24-hour time points, reflecting the progression of ischemia with
time. Nevertheless, 792 and 167 genes were found to be commonly
upregulated or downregulated at both 6 and 24 hours (Fig. 2;
supplementary material Tables S6, S7).
We next categorized the affected genes on the basis of their
function under gene ontology (GO) terms of biological process
(3440 and 6826 induced genes, and 1398 and 3531 suppressed genes
at 6 and 24 hours, respectively), molecular function (875 and 1732
induced genes, and 394 and 1021 suppressed genes at 6 and 24
hours, respectively) and cellular component (1788 and 3522
induced genes, and 762 and 2015 suppressed genes at 6 and 24
hours, respectively). The functionally categorized genes are
presented graphically in Fig. 3. It should be noted that the same
gene was sometimes included in different functional categories,
thus making the total numbers seem inflated. In the major category
of biological process, the subcategory of cellular process showed
the largest number of gene changes (induction and suppression),
followed by biological regulation, regulation of biological process,
and metabolic process. In the second major category of molecular
function, the binding activity subcategory included the most cases
of changed gene expression, followed by catalytic activity, and
molecular transducer activity. In the third major category of
cellular component, the major gene changes were in the cell, cell
part, followed by the organelle, and extracellular part subcategories.
From these data, it can be seen that, in general, the change in the
pattern of gene expression was time-dependent, i.e. the number of
Fig. 1. Workflow from sampling and grinding
of the brain hemisphere, total RNA
extraction, and DNA microarray analysis of
the ischemic brain (ipsilateral hemisphere).
(A)Mouse whole brain showing the ipsilateral
(right; boxed region) and contralateral (left)
hemispheres. Brain tissues were ground to a fine
powder in liquid nitrogen and stored at –80°C.
(B)Total RNA extraction from the finely
powdered brain tissues. Total RNA quality was
confirmed by both agarose-gel electrophoresis
and NanoDrop spectrophotometry. (C)DNA
microarray chip showing the hybridized sample
combinations (Sham  PMCAO at 6 and 24
hours) and dye-swap (Cy3 vs Cy5).
Fig. 2. Differentially expressed genes in the ipsilateral hemisphere at 6
and 24 hours. The numbers above each bar indicate the selection of genes
from the total microarray datasets within a defined fold range of greater than
1.5- or 2.0-fold and less than 0.75- or 0.5-fold. The gene lists are presented in
supplementary material Tables S2-S7.
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instances of increased and decreased gene expression was higher
at 24 hours than at 6 hours. This is in line with the fact that cellular
death progresses with time, i.e. following PMCAO the volume of
ischemic brain tissue increases to cover almost the entire right
hemisphere by 24 hours.
Changes in gene expressions reveal differential time-dependent
patterns
In the ipsilateral hemisphere and at the two time points investigated
in this analysis, major and minor trends were observed in relation
to gene expression and/or function in response to ischemia. In a
major trend, we were able to identify genes that were dramatically
up- or downregulated at 6 and 24 hours; these can be considered
as early (pre-ischemia)- and late (post-ischemia)-responsive genes.
However, it must be emphasized that instances of upregulation were
more dramatic in the ischemic brain, indicating that ischemia
increases gene induction rather than gene suppression. This is
understandable given the fact that ischemic damage increases with
time, leading to irreversible apoptosis or cell death. For example,
S100a5 was the most highly upregulated gene (41.25-fold) at 6 hours
but at 24 hours showed only a 12.97-fold induction, whereas Mmp8
and Mmp3 were increased 128.73- and 115.72-fold, respectively,
at 24 hours but only showed a 12.44- and 6.23-fold induction,
respectively, at 6 hours. This trend differentiates early (S100a5)-
and late (Mmp8/3)-responsive gene expression in the ischemic
brain. All the gene expression data are included in supplementary
material Tables S2-S7 (see also later).
We further utilized the pathway-focused or specific-disease-
states-focused gene classifications available on the QIAGEN
website (SABiosciences; www.sabiosciences.com) to reveal the
trend of predominant pathways affected in the ipsilateral (ischemic)
hemisphere (Fig. 4). In general, it can be seen that most of the
categories show an increasing trend of gene up- or downregulation
with time. The up- and downregulated genes in each functional
classification at 6 and 24 hours after ischemia are listed in
supplementary material Table S8. However, the trends of gene
Fig. 3. Functional categorization of the differentially expressed genes based on Gene Ontology (GO). The genes were grouped into the major categories of
biological function, molecular function and cellular component. Numbers above each graph represent gene numbers for each subcategory.D
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Fig. 4. See next page for legend.
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Fig. 4. Pathway- and disease-states-focused gene classification. The up- and downregulated genes at 6 (A) and 24 (B) hours after ischemia (ipsilateral
hemisphere) were classified based on the available categories of more than 100 biological pathways or specific disease states in the SABiosciences PCR array list
(QIAGEN; www.sabiosciences.com) for Mus musculus. The numbers in the y-axis represent number of genes in each category, which are indicated on the x-axis.
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quantity (numbers) and quality (function) in the respective
pathways varied between the two time points studied. This can be
expected because the ischemic area progresses with time in the
ipsilateral hemisphere. For example, genes related to endothelial
cell biology, inflammatory response, autoimmunity pathways and
atherosclerosis showed strongly increased expression at 24 hours.
By contrast, DNA repair genes were only seen at the 24-hour but
not the 6-hour time point. Some of these gene expression trends
are discussed below in relation to ischemia.
S100 calcium-binding protein family
The S100 protein family constitutes the largest group of Ca2+-
binding proteins of the EF-hand type involved in cation homeostasis
(Schafer and Heizmann, 1996; Heizmann and Cox, 1998). We found
that the mRNA level corresponding to the S100a5 gene is increased
in the ischemic brain. S100a5 is known as an unusual member of
the S100 protein family in that it has a high affinity for Ca2+, Zn2+
and Cu2+. S100a5 immunoreactivity has been found in neuronal
dendrites, but not in neuronal soma or any glial cells in the rat
brain (Schäfer et al., 2000). To the best of our knowledge, the
function of S100a5 in the ischemic brain is not known, but another
family member, S100b, has been shown to exhibit Cu2+ affinity and
suppress the hemolysis of mouse erythrocytes induced by CuCl2.
Furthermore, when Escherichia coli is transformed with a vector
containing S100b cDNA, cell damage as a result of copper-induced
oxidative stress is also reduced (Nishikawa et al., 1997). It is
Fig. 5. mRNA expression profiles of 16 differentially expressed genes. (A)Upregulated genes; (B) downregulated genes. Gel images on top show the PCR
product bands stained with ethidium bromide; the band intensities are also presented graphically below for clarity. Lane numbers 1-8 indicate sham control
(lanes 1, 3, 5 and 7) and PMCAO (lanes 2, 4, 6 and 8) treatment, respectively. RT-PCR was performed as described in the Methods and the primers are detailed in
supplementary material Table S1.
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tempting to speculate that S100a5 might also exert such a protective
role. It should be noted, however, that this gene has been previously
identified as a hypoxia-inducible gene on the basis of its
upregulation after 6 hours of hypoxia (Tang et al., 2006). S100a5
might protect neurons against acute ischemic damage. Around ten
S100 family members were reported and reviewed in 2005 with
respect to nervous system function and neurological disorders
(Zimmer et al., 2005). The importance of the S100 proteins with
respect to their application in clinical practice has also recently been
reviewed, and there are now at least 25 members in this family
(Sedaghat and Notopoulos, 2008). In our analysis, we also identified
changes in the expression of other members of the S100 family,
namely S100a9 and S100a8 (upregulated at 6 and 24 hours), and
S100a11, S100a14, S100a4, S100a6, S100a3, S100a15 and S100a10
(upregulated at 24 hours only). The early and late upregulation of
these genes suggests their involvement in both signal transduction
processes and the inflammatory response.
Matrix metalloproteinases
Two genes belonging to the matrix metalloproteinase (MMP)
enzyme family, namely Mmp8 and Mmp3, showed the highest level
of upregulation in response to ischemia. As the name suggests,
these enzymes are known to participate in the degradation of
components of the extracellular matrix. The MMPs constitute a
family of more than 20 endopeptidases (Yong et al., 2001; Crocker
et al., 2004; Cauwe et al., 2007). Although the induction and role
of Mmp8 in ischemia has not previously been reported, this gene
has been implicated in inflammatory arthritis (Cox et al., 2010),
lung injury (Albaiceta et al., 2010), atherosclerosis (Laxton et al.,
2009) and periodontitis (Kuula et al., 2009). Taken together with
the published reports of Mmp8 function, our finding suggests a
protective role for Mmp8 in ischemic tissues. This could occur via
the processing of anti-inflammatory cytokines and chemokines by
MMP8. Because MMP8 is a proteinase, it might cleave and release
certain signaling factors in the extracellular matrix at a very early
stage after ischemia (6 hours), and then subsequently contribute
to the activation of defensive responses at a semi-acute phase (24
hours). MMP8 is also known as neutrophil collagenase and is
released from activated neutrophils; this suggests that the activated
neutrophil starts invasion or migration processes (Dejonckheere
et al., 2011).
By contrast, the Mmp3 gene has been associated with the
pathogenesis of a number of diseases, including stroke, brain trauma
and neuroinflammation (Rosenberg, 2002). The group of Rosenberg
et al. also previously reported MMP3 and MMP9 immunoreactivity
at 24 hours after ischemia (Rosenberg et al., 2001); MMP3 and MMP9
were found to colocalize with activated microglia and ischemic
neurons. It has been previously reported that a small amount of
MMP3 is needed to activate proMMP9 in endothelial cells,
amplifying changes in brain blood vessel properties (Rosenberg et
al., 2001). Recently, an important study regarding the role of MMP3
inside the cell was published, in which it was shown that the
catalytically active, cleaved form of MMP3 (actMMP3) is produced
intracellularly in oxidatively stressed neurons and plays a role in
apoptotic signaling (Choi et al., 2008). The same group further
demonstrated the role of MMP3 in neuronal apoptotic signaling
downstream of caspase-12 during endoplasmic reticulum stress (Kim
et al., 2010). MMP3 might act as an apoptosis-inducing factor as
well as a protease in the ischemic brain. Interestingly, our analysis
also identified a further five Mmp gene family members, including
Mmp9, Mmp12, Mmp13, Mmp14 and Mmp19. The MMP9 protein
has been reported to increase after cerebral focal ischemia in rats
(Romanic et al., 1998). We also found a 4.28-fold increase in Mmp9
expression at 24 hours after ischemia, which is in line with the
observation of MMP9 protein expression. It has been recently
reported that MMP9 released from bone-marrow-derived cells
contributes to the disruption of the blood-brain barrier that causes
brain edema in stroke (Wang et al., 2009). Thus, the upregulation of
MMP9 might correlate with brain edema.
In all, these results suggest another novel finding indicating the
involvement of multiple MMPs in the ischemic brain. However,
given the high levels of induction of Mmp8 and Mmp3, we
hypothesize a particularly important role for these two family
members in ischemia.
Chemokines
The chemokines are chemotactic cytokines that, together with their
receptors, which are expressed on leukocytes, play crucial roles in
the extravasation and migration of leukocytes under inflammatory
conditions (Gerard and Rollins, 2001; Semple et al., 2010). Two
classes of chemokines have been identified on the basis of their
structure, namely CXC and CC. The C refers to the two N-terminal
cysteine residues, and the classes are defined depending on whether
or not there is an amino acid between them (i.e. C-x-C versus C-
C) (Rossi and Zlotnik, 2000). In addition, chemokines are reported
to be important players in stroke and its pathogenesis (Semple et
al., 2010; Brait et al., 2011). Brait et al., using a PCR array of 84
genes, recently reported the expression of chemokines in ischemic
mouse brain at 4, 24 and 72 hours after 0.5 hours of cerebral
ischemia (Brait et al., 2011).
Similarly, in our study we also identified changes in the
expression of numerous chemokine-related genes, including genes
encoding for chemokine (C-x-C motif and C-C motif ) ligands that
were highly upregulated by ischemic stress. For example, expression
of the Cxcl1 gene was increased 13.25-fold and 69.79-fold at 6 and
24 hours, respectively, whereas the Cxcl3 gene was upregulated
(117.79-fold) at 24 hours only. These trends reveal the differential
and specific regulation of the Cxcl family members in the brain.
Other than these two genes, we also identified Cxcl2, Cxcl10, Cxcl4
and Cxcl7 as being upregulated following 6 and 24 hours of
ischemia, whereas Cxcl11, Cxcl16 and Cxcl13 were found to be
upregulated at 24 hours only. In the C-C motif class, we identified
the Ccl4 gene as being upregulated 17.80- and 44.63-fold at 6 and
24 hours. Ccl2, Ccl7, Ccl24, Ccl11, Ccl17, Ccl9, Ccl5, Ccl12 and
Ccl6 were also upregulated at both time points. However, the Ccl19
gene was found to be upregulated specifically at 24 hours.
In addition, the chemokine receptor genes Ccr2, Ccr7 and Ccr1
were induced at 24 hours, whereas the chemokine-receptor-like
gene Ccrl2 was induced at both 6 and 24 hours. Although there
has been some discussion regarding the pharmacological inhibition
of chemokine ligands and receptors as a means of reducing post-
ischemic neuronal damage and cell death, no chemokine has yet
emerged as the most valid target (see also Brait et al., 2011).
Nonetheless, our study provides information on numerous
differentially expressed chemokine genes whose further analysis
might shed light on their role in the ischemic brain.
D
ise
as
e 
M
od
el
s &
 M
ec
ha
ni
sm
s  
    
   D
M
M
dmm.biologists.org278
Ischemic mouse brain transcriptomeRESOURCE ARTICLE
Interleukins
Another example of a highly induced gene was interleukin 6 (Il6),
which is also known to be an important inflammatory cytokine in
ischemic brain tissue (Ohtaki et al., 2006). Expression of this gene
was 10.35-fold and 89.23-fold upregulated at 6 and 24 hours,
respectively. IL-6, which has been identified as a B-cell stimulating
factor (Kishimoto, 1989), belongs to a subfamily of cytokines that
include leukemia inhibitory and ciliary neurotrophic factors and
use gp130 as a common receptor subunit. IL-6 has been previously
shown to play a role in neurodegeneration rather than
neuroprotection in cerebral ischemia (Clark et al., 2000). Another
report also showed that the infarct volume after temporary MCAO
is similar in wild-type and knockout mice lacking IL-6 (Pera et al.,
2004). Endogenous IL-6, which transiently increases in the acute
phase of cerebral ischemia, plays a crucial role in preventing
damaged neurons from undergoing apoptosis; this role might be
mediated by Stat3 activation. IL-6 signaling could be used as a new
target for stroke therapy, but exogenous IL-6 administration is
unlikely to be effective for treating brain ischemia given that
excessive IL-6 sometimes generates harmful effects, such as
inducing fever (Yamashita et al., 2005). Our results are in line with
previous reports showing a crucial role for Il6 in brain ischemia
progression.
In contrast to Il6, IL1-delta (Mus musculus interleukin 1 family,
member 5) expression is suppressed after ischemia (0.49-fold and
0.20-fold downregulated at 6 and 24 hours, respectively). IL1-delta
is a subtype of the IL-1 ligand, which shows strong homology to
the IL1 receptor antagonist IL1ra (Debets et al., 2001). Although
the function of IL1-delta in the brain is still unclear, it was reported
that IL1-delta blocked IL1-epsilon function, which activates the
transcription factor NF-kappa-B (NFB) through the orphan
receptor IL1Rrp2. The NFB signal is activated by inflammatory
responses; some anti-inflammatory drugs, various non-steroidal
anti-inflammatory drugs and glucocorticoids are potent inhibitors
of NFB (D’Acquisto et al., 2002). NFB activation also contributes
to the progress of brain ischemia (Harari et al., 2010). In addition,
IL1-delta mRNA is strongly downregulated in TNF-treated
human adipocytes (Do et al., 2006). IL1-delta might act as an anti-
inflammatory or cytoprotective factor in brain ischemia.
The DNA microarray analysis in the present study provided new
information for the involvement of numerous interleukin family
members in brain ischemia. We identified interleukin-1 receptor
type 2 (Il1r2), Il8rb (), Il1a (), Il17rb (homolog short isoform
precursor), Il19, Il31ra, Il1b, Il4ra, Il11 and Il1r1 as being
upregulated at 6 and 24 hours, whereas Il18rb, Il7r and Il1rap
(receptor accessory protein) were induced at 6 hours only. At 24
hours, the Il1rn (receptor antagonist), Il18rap, Il21, Il1f9 (family),
Il12rb1, Il13ra1, Il2rg (), Il1rl1 (receptor-like), Il28ra, Il12b,
Il13ra2, Il5 and Il6ra genes were found to be specifically
upregulated. These results again reflect the importance of global
gene profiling approaches to investigate the brain.
Confirmation of gene expression by RT-PCR and differential
expression of their mRNAs in the ipsilateral and contralateral
hemispheres
For confirmation of alterations in gene expression by DNA
microarray, we randomly selected 15 genes with annotated
functions that were highly up- or downregulated in the ischemic
brain (eight genes in each group, as listed in supplementary
material Table S1). The mRNA expression profiles obtained by
reverse-transcriptase PCR (RT-PCR) (Fig. 5) revealed that the DNA
microarray data could be validated using appropriate primer
design. In addition, we also examined how those genes, which
displayed altered expression patterns in the ipsilateral (ischemic)
hemisphere, behaved in the contralateral (non-ischemic)
hemisphere. This was done (1) to confirm that these genes are
indeed ischemia-related, and (2) to uncover any potential bilateral
effects. We also reasoned that this parallel analysis would reveal
any effects of saline injection on gene expression.
Upregulated genes
RT-PCR analysis revealed that S100a5 mRNA was also expressed
in the non-ischemic region (lanes 6 and 8, Fig. 5A). This was a
surprising finding, which we are unable to fully explain.
Nevertheless, it is possible that the S100a5 gene was influenced
bilaterally following ischemia, i.e. its expression was modulated by
events occurring in the ischemic hemisphere. The other member
of this family, S100a8, was primarily expressed in the ischemic
hemisphere, but not (or only minimally) expressed in the non-
ischemic hemisphere, suggesting that S100a5 and S100a8 show
differential expression in the non-ischemic hemisphere. In the case
of the heat-shock protein (HSP) 1a (Hsp1a) gene, a high level of
expression was confirmed in the ischemic hemisphere at 6 hours.
However, this gene was also constitutively expressed, albeit at low
levels, in the brain, which is logical considering the important role
of HSPs in cellular processes. Interestingly, a recent study has shown
that astrocyte targeted overexpression of HSP72 (or SOD) can
reduce neuronal vulnerability to forebrain ischemia (Xu et al., 2010).
RT-PCR analysis revealed that Mmp3 was more highly expressed
than Mmp8, although both genes showed a high level of expression
at 24 hours in the ischemic region. Surprisingly, Mmp3 and Mmp8
genes showed dramatically opposite regulation in the non-ischemic
region. Considering the relatively high level of expression of Mmp3
in the contralateral hemisphere of the sham controls, the possibility
that the increase in its mRNA expression was a result of the saline
injection cannot be ruled out. In a similar fashion, the Cxcl1 gene
was strongly induced in the ischemic region, but not in the non-
ischemic tissue. The Mmp3, CxCl1, Ccl4 and Il6 genes of sham
controls in the contralateral hemisphere were more highly
expressed than on the ipsilateral side, suggesting that the
upregulation might be a result of wounding, i.e. by the
intracerebroventricular saline injection.
Downregulated genes
To date, no known brain function of the Smg6 (Smg6-homolog,
nonsense mediated mRNA decay factor, C. elegans) gene has been
described. Our findings provide the first reported expression data
of this gene in the mouse brain and its downregulation under
ischemia. The Gm711 gene is a probable protein-kinase-like
protein, the expression of which has again not been previously
reported in the brain. However, our results demonstrated that it
is downregulated following 24 hours of ischemia. Lama1, which
encodes for laminin, an extracellular matrix constituent similar
to the MMPs, was prominently downregulated in the ischemic
region. A previous report has described laminin degradation in
the CA1 and CA2 areas of C57BL/6 mice subjected to 20 minutes
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of global cerebral ischemia (Lee et al., 2009). Furthermore, this
degradation could be reduced by the use of the tetracycline
antibiotic doxycycline via the inhibition of MMP9. Tnfsf10, the
tumor necrosis factor (ligand) superfamily member 10 gene,
which is constitutively expressed in the brain, was found to be
dramatically reduced in the ischemic region, and also to some
extent in the non-ischemic region. Also called the proapoptotic
cytokine TNF-related apoptosis-inducing ligand or TRAIL, its
function in ischemia remains to be clarified. Expression of the
Aff2 gene, which has been implicated in neurodevelopmental
diseases, is reduced following ischemia (Vogel and Gruss, 2009).
The Ankk1 gene is a predicted kinase shown to be expressed
exclusively in astrocytes in the adult central nervous system (CNS)
in humans and rodents (Hoenicka et al., 2010). Although its
function in relation to ischemia remains unknown, its mRNA level
was reduced in the ischemic region. Finally, the p2ry12 gene
encodes the purinergic P2Y receptor, G-protein coupled 12
protein, with a role in the vessel wall response to arterial injury
and thrombosis. Downregulation of this gene was seen in both
the ischemic and non-ischemic regions.
Concluding remarks
Our study provides the first inventory of ischemia-related and/or
responsive genes in the mouse brain. On the basis of a high-
throughput transcriptomics approach on a 44K DNA microarray
chip, we have identified not only numerous genes with potential
involvement in the regulation of brain ischemia, but also most of
the genes that have previously been reported in targeted studies.
For example, the most prominent gene with known involvement
in regulating ischemia identified here was Il6. Apart from IL-6 and
related interleukins, we also found that the Ca2+-binding protein
S100a and members of the matrix metalloproteinase and
chemokine gene families showed the most significant changes
following 6 and 24 hours of ischemia. Interestingly, many genes
also showed differential expression in the non-ischemic
contralateral hemisphere, revealing the identity of specific ischemia-
related genes. Our study further highlights the usefulness of global
gene expression profiling in searching for changes in gene
expression and delineating the molecular events in a defined
experimental model, in this case the ischemic brain. Elucidating
the expression pattern of each differentially expressed gene in
specific brain regions and determining the level of protein synthesis
will be the next experimental step. These future studies will provide
information on the sites of gene expression and increase our
understanding of the functional role of various genes in response
to an ischemic injury. Moreover, and consistent with the long-term
goals of our group, the identified gene candidates will inform our
investigations of the effect of target neuropeptide(s) in potentially
controlling and/or reversing ischemia.
METHODS
Animals and husbandry
C57BL/6J mice purchased from Charles River (Kanagawa, Japan)
were used in this study. Thirty male mice (9 weeks old; ~25-35 g
body weight) were housed at the Animal Institution in Showa
University in acrylic cages (eight mice per cage) at 23°C, and
maintained with a standard 12-hour light/dark cycle with optimum
humidity and temperature control. All animals were given access
to tap water and laboratory chow ad libitum. All animal care and
experimental procedures were approved by the Institutional Animal
Care and Use Committee of Showa University (School of Medicine),
Tokyo, Japan.
PMCAO and sham control
To generate the PMCAO model, mice were anesthetized with 4%
sevoflurane (induction) and 2% sevoflurane (maintenance) in a 30%
O2 and 70% N2O gas mixture via a face mask. An incision was then
made in the cervical skin followed by opening of the salivary gland
and visualization of the right common carotid artery. The external
carotid artery was exposed through a midline cervical incision. For
PMCAO, we used the intraluminal filament technique, whereby a
7-0 monofilament nylon suture with its tip slightly rounded by
heating was inserted into the common carotid artery, then
positioned in the middle cerebral artery (supplementary material
Fig. S1D), after which the wound was sutured closed. In sham
control animals, the external carotid artery was exposed and then
the wound was sutured. In both the sham control and PMCAO
cases, 1 l of saline (0.9% NaCl) was injected intracerebroventrically,
and the animals were returned to their cages. A total of four groups
were prepared: two groups of six and seven mice in the PMCAO
cohorts at 6 and 24 hours after operation, respectively, and five
mice each in the control (sham) groups at 6 and 24 hours after
operation, respectively. We used three mice each in PMCAO groups
that exhibited neurological grades G1 and G2 (Ohtaki et al., 2006)
and three mice each at random in sham groups for the subsequent
downstream analysis. Some of the mice were examined for ischemia
by triphenyltetrazolium chloride (TTC) staining of brain sections
(2 mm slices) at 37°C for 10 minutes (Ohtaki et al., 2006; Dogrukol-
Ak et al., 2009) using some of the PMCAO mice brains
(supplementary material Fig. S1E).
Dissection of brain and storage of samples
At 6 or 24 hours post-injection of saline, the mice were removed
from their cages, decapitated and their brains carefully removed
on ice. The left (contralateral) and right (ipsilateral) hemispheres
were dissected and placed in 2 ml Eppendorf tubes, which were
then quickly immersed in liquid nitrogen before being stored in
–80°C prior to further analysis (Fig. 1A).
Grinding of the brains and total RNA extraction
The deep-frozen brain hemispheres were transferred to a pre-
chilled (in liquid nitrogen) mortar and ground with a pestle to a
very fine powder with liquid nitrogen. The scheme for preparation
of fine tissue powders for downstream gene analysis is given in Fig.
1A (see also Masuo et al., 2011a; Masuo et al., 2011b). The
powdered samples were transferred to 2 ml Eppendorf microtubes
and stored in aliquots at –80°C until used for extraction of total
RNA or protein. Total RNA was extracted from ~60 mg sample
powder using the QIAGEN RNeasy Mini Kit (QIAGEN,
Germantown, MD). The total RNA extraction protocol is briefly
illustrated in Fig. 1B (see also supplementary material Fig. S2)
(Masuo et al., 2011b; Ogawa et al., 2011). To verify the quality of
this RNA, the yield and purity were determined
spectrophotometrically (NanoDrop, Wilmington, DE) and visually
confirmed using formaldehyde-agarose gel electrophoresis (Fig. 1B;
supplementary material Fig. S3).
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cDNA synthesis and RT-PCR
To validate the total RNA quality and subsequently synthesized
cDNA, RT-PCR was performed. Two commonly used genes,
namely GAPDH and -actin, were used for RT-PCR. The 3-UTR
gene-specific primers are shown in supplementary material Table
S1. Briefly, total RNA samples (from both the ipsilateral and
contralateral hemispheres) were first DNase-treated with RNase-
free DNase (Stratagene, Agilent Technologies, La Jolla, CA). First-
strand cDNA was then synthesized in a 20 l reaction mixture with
an AffinityScript QPCR cDNA Synthesis Kit (Stratagene) according
to the protocol provided by the manufacturer, using 1 g total RNA
isolated from each control and treated brain sample. The reaction
conditions were: 25°C for 5 minutes, 42°C for 5 minutes, 55°C for
40 minutes and 95°C for 5 minutes. The synthesized cDNA was
made up to a volume of 50 l with sterile water supplied in the kit.
The reaction mixture contained 0.6 l of the first-strand cDNA, 7
pmols of each primer set and 6.0 l of the Emerald Amp PCR
Master Mix (2 premix) (TaKaRa Shuzo, Shiga, Japan) in a total
volume of 12 l. Thermal-cycling (Applied Biosystems, Tokyo,
Japan) parameters were as follows: after an initial denaturation at
97°C for 5 minutes, samples were subjected to a cycling regime of
20-40 cycles at 95°C for 45 seconds, 55°C for 45 seconds and 72°C
for 1 minute. At the end of the final cycle, an additional extension
step was carried out for 10 minutes at 72°C. After completion of
the PCR the total reaction mixture was spun down and mixed (3
l) before being loaded into the wells of a 1.2/1.8% agarose [Agarose
(fine powder) Cat no. 02468-95, Nacalai Tesque, Kyoto, Japan] gel.
Electrophoresis was then performed for ~22 minutes at 100 Volts
in 1 TAE buffer using a Mupid-ex electrophoresis system
(ADVANCE, Tokyo, Japan). The gels were stained (8 l of 10 mg/ml
ethidium bromide in 200 ml 1 TAE buffer) for ~7 minutes and
the stained bands were visualized using an UV-transilluminator
(ATTO, Tokyo, Japan). The RT-PCR protocol used in this study is
detailed in supplementary material Fig. S5.
DNA microarray analysis in the ipsilateral (right) hemisphere
A mouse 4x44K whole genome oligo DNA microarray chip
(G4122F, Agilent Technologies, Palo Alto, CA) was used for global
gene expression analysis using the ipsilateral (ischemic) hemisphere.
Total RNA (900 ng; 300 ng each replicate pooled together) was
labeled with either Cy3 or Cy5 dye using an Agilent Low RNA Input
Fluorescent Linear Amplification Kit (Agilent). Fluorescently
labeled targets of control (sham) as well as treated (PMCAO)
samples were hybridized to the same microarray slide with 60-mer
probes (Fig. 1C). As illustrated in Fig. 1C, in this experiment we
compared the PMCAO mice to sham controls, i.e. the ipsilateral
brain region of the PMCAO mice was compared with the same
right hemisphere of the control mice (Fig. 1A). A flip labeling (dye-
swap or reverse labeling with Cy3 and Cy5 dyes) procedure was
followed to nullify the dye bias associated with unequal
incorporation of the two Cy dyes into cDNA (Rosenzweig et al.,
2004; Altman, 2005; Martin-Magniette et al., 2005). Briefly, to select
differentially expressed genes, we identified genes that were
upregulated in chip 1 (Cy3/Cy5 label for control and treatment,
respectively, at 6 hours) but downregulated in chip 2 (Cy3/Cy5 label
for treatment and control, respectively, at 6 hours) for the ipsilateral
brain hemisphere. The same selection criteria were applied for chips
3 and 4 (24 hours). The use of a dye-swap approach provides a
more stringent selection condition for changed gene expression
profiling than the use of a simple single/two-color approach
(Hirano et al., 2007; Hirano et al., 2008; Hirano et al., 2009; Tano
et al., 2010a; Tano et al., 2010b; Ogawa et al., 2011).
Hybridization and wash processes were performed according to
the manufacturer’s instructions, and hybridized microarrays were
scanned using an Agilent Microarray scanner, G2565BA. For the
detection of significantly differentially expressed genes between
control and treated samples, each slide image was processed by
Agilent Feature Extraction software (version 9.5.3.1). Briefly, (1) this
program measured Cy3 and Cy5 signal intensities of whole probes;
(2) dye-bias tends to be signal intensity dependent, and therefore the
software selected probes using a set by rank consistency filter for
dye normalization; (3) normalization was performed by LOWESS
(locally weighted linear regression), which calculates the log ratio of
dye-normalized Cy3 and Cy5 signals, as well as the final error of the
log ratio; (4) the significance (P) value was based on the propagate
error and universal error models; (5) the threshold of significance
for differentially expressed genes was <0.01 (for the confidence that
the feature was not differentially expressed); and (6) erroneous data
RESOURCE IMPACT
Background
The early diagnosis and treatment of patients who have suffered episodes
of brain or myocardial infarction is crucial to avoid the effects of ischemia
and improve survival outcomes. The obstruction of cerebral blood flow
induces time-dependent pathophysiological changes in brain tissue,
including tissue necrosis, and can cause death if the situation is not
resolved quickly. Patients affected by ischemic brain disease can suffer
from many symptoms, including neurological (e.g. palsy, speech
difficulties) and psychological (e.g. decrease in memory, anxiety)
problems that decrease quality of life. The most radical therapy for brain
ischemia is thrombolytic reperfusion of the occluded artery, which
restores blood flow to peripheral regions. However, the most important
aspects of therapy for brain ischemia after onset of disease is that the
patient adopts a healthy lifestyle (including diet, exercise and rest) and
undergoes long-term rehabilitation to improve residual brain function.
Results
This study uses a genome-wide global gene expression approach to
characterize the molecular events occurring in ischemic brain tissue in
mice. Using the whole genome mouse 4x44K DNA microarray system and
a dye-swap approach, the study reveals changes in the expression of
several hundred genes in the mouse brain at both 6 and 24 hours
following an episode of ischemia. As expected, genes linked to immune
and inflammatory responses are expressed more strongly in ischemic
tissue; however, numerous genes and pathways not previously linked
with ischemia are also identified.
Implications and future directions
This study uncovers the identity of the many gene candidates that are up-
or downregulated in the ischemic brain. Comparative and time-
dependent analyses differentiate early and late changes in gene
expression, providing new hypotheses regarding pathways that regulate
an ischemic episode and its progression. Gene candidates identified in
this study could be further investigated for their role in brain ischemia
and their potential to be targeted for therapy using knockout mice.
Finally, this study provides new clues about the capacity of certain
neuropeptides to reverse the effects of ischemia. Further genetic and
proteomic analysis of mouse models of ischemia will continue to help to
unravel the molecular basis underlying this disease.
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generated owing to artifacts were eliminated before data analysis
using the software. The outputs of microarray analysis used in this
study are available under the series number GSE 28201 at the NCBI
Gene Expression Omnibus (GEO) public functional genomics data
repository (http://www.ncbi.nlm.nih.gov/geo/info/linking.html).
To validate the microarray data (ipsilateral hemisphere), RT-PCR
was also performed on randomly up- and downregulated genes
using 3-UTR-specific gene primers. In parallel, we also examined
the gene expression profile in the contralateral (left) hemisphere
by using the same genes for RT-PCR analysis.
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